biostudies-literatureUnknown97(5)Wilson WH<h4>Background</h4>A phase II trial of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R) from the National Cancer Institute showed promising activity in untreated diffuse large B-cell lymphoma. The Cancer and Leukemia Group B conducted a study to determine if these results could be reproduced in a multi-institutional setting.<h4>Design and methods</h4>The study included 69 patients with untreated diffuse large B-cell lymphoma at least 18 years of age and at least stage II. Radiaton therapy was not permitted on study. Median age was 58 years (range 23-83) and 40% had high-intermediate or high International Prognostic Index risk. Immunohistochemical biomarkers for cell of origin and proliferation were performed.<h4>Results</h4>With a mHaematologica758-65https://www.ebi.ac.uk/biostudies/studies/S-EPMC3342980biostudies-literatureA Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.PMC3342980Jung SHHsi EDHurd DJohnson JPorcu PDunleavy KMartin SECanellos GJones DCancer Leukemia Group BWilson WHCheson BDZelenetz ADCzuczman MSaid JLai RChadburn AfalseA Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.<h4>Background</h4>A phase II trial of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (DA-EPOCH-R) from the National Cancer Institute showed promising activity in untreated diffuse large B-cell lymphoma. The Cancer and Leukemia Group B conducted a study to determine if these results could be reproduced in a multi-institutional setting.<h4>Design and methods</h4>The study included 69 patients with untreated diffuse large B-cell lymphoma at least 18 years of age and at least stage II. Radiaton therapy was not permitted on study. Median age was 58 years (range 23-83) and 40% had high-intermediate or high International Prognostic Index risk. Immunohistochemical biomarkers for cell of origin and proliferation were performed.<h4>Results</h4>With a m2012-01-01T00:00:00Z2012 May2025-04-18T14:48:21.052Z2019-03-27T00:52:57ZS-EPMC33429802213377210.3324/haematol.2011.056531